Correlation Between Veracyte and Voyager Therapeutics

Can any of the company-specific risk be diversified away by investing in both Veracyte and Voyager Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Voyager Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Voyager Therapeutics, you can compare the effects of market volatilities on Veracyte and Voyager Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Voyager Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Voyager Therapeutics.

Diversification Opportunities for Veracyte and Voyager Therapeutics

-0.31

Correlation Coefficient

Veracyte  Voyager Therapeutics

Very good diversification

The 3 months correlation between Veracyte and Voyager is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Voyager Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Voyager Therapeutics and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Voyager Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Voyager Therapeutics has no effect on the direction of Veracyte i.e., Veracyte and Voyager Therapeutics go up and down completely randomly.

Pair Corralation between Veracyte and Voyager Therapeutics

Given the investment horizon of 90 days Veracyte is expected to generate 0.48 times more return on investment than Voyager Therapeutics. However, Veracyte is 2.06 times less risky than Voyager Therapeutics. It trades about 0.13 of its potential returns per unit of risk. Voyager Therapeutics is currently generating about 0.02 per unit of risk. If you would invest  3,351  in Veracyte on September 26, 2024 and sell it today you would earn a total of  767.00  from holding Veracyte or generate 22.89% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Voyager Therapeutics

Veracyte

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Voyager Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Voyager Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady technical and fundamental indicators, Voyager Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Veracyte and Voyager Therapeutics

The main advantage of trading using opposite Veracyte and Voyager Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Voyager Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will offset losses from the drop in Voyager Therapeutics' long position.

The idea behind Veracyte and Voyager Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.